NCT00506402View on ClinicalTrials.gov

A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

January 31, 2009

Study Completion Date

April 30, 2009

Conditions
Hematological MalignanciesMyelodysplasiaAgnogenic Myeloid Metaplasia
Interventions
DRUG

MKC-1

Capsule, 30 mg and 100 mg, BID, continuous dosing

Trial Locations (1)

Unknown

Princess Margaret Hospital, Toronto

Sponsors
All Listed Sponsors
lead

CASI Pharmaceuticals, Inc.

INDUSTRY